- Home
- ARVN vs CTO Comparison
ARVN vs CTO Comparison
Compare ARVN & CTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARVN
- CTO
- Stock Information
- Founded
- ARVN 2015
- CTO 1902
- Country
- ARVN United States
- CTO United States
- Employees
- ARVN N/A
- CTO N/A
- Industry
- ARVN Biotechnology: Pharmaceutical Preparations
- CTO Real Estate Investment Trusts
- Sector
- ARVN Health Care
- CTO Real Estate
- Exchange
- ARVN Nasdaq
- CTO Nasdaq
- Market Cap
- ARVN 676.2M
- CTO 552.9M
- IPO Year
- ARVN 2018
- CTO N/A
- Fundamental
- Price
- ARVN $10.59
- CTO $17.47
- Analyst Decision
- ARVN Buy
- CTO Strong Buy
- Analyst Count
- ARVN 23
- CTO 3
- Target Price
- ARVN $17.80
- CTO $22.00
- AVG Volume (30 Days)
- ARVN 2.3M
- CTO 274.1K
- Earning Date
- ARVN 11-05-2025
- CTO 10-28-2025
- Dividend Yield
- ARVN N/A
- CTO 8.71%
- EPS Growth
- ARVN N/A
- CTO N/A
- EPS
- ARVN N/A
- CTO N/A
- Revenue
- ARVN $312,300,000.00
- CTO $146,948,000.00
- Revenue This Year
- ARVN N/A
- CTO $20.84
- Revenue Next Year
- ARVN N/A
- CTO $6.72
- P/E Ratio
- ARVN N/A
- CTO N/A
- Revenue Growth
- ARVN 93.86
- CTO 23.84
- 52 Week Low
- ARVN $5.90
- CTO $15.07
- 52 Week High
- ARVN $27.00
- CTO $20.88
- Technical
- Relative Strength Index (RSI)
- ARVN 59.44
- CTO 68.79
- Support Level
- ARVN $9.27
- CTO $16.91
- Resistance Level
- ARVN $11.51
- CTO $17.65
- Average True Range (ATR)
- ARVN 0.53
- CTO 0.35
- MACD
- ARVN 0.02
- CTO 0.08
- Stochastic Oscillator
- ARVN 59.15
- CTO 87.88
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
About CTO CTO Realty Growth Inc.
CTO Realty Growth Inc is a real estate investment trust company, that owns income properties comprised of approximately 2.7 million square feet in diversified markets in the United States. Its portfolio of assets consists of Income Properties Portfolio, management services, Commercial Loan and Investments.